
There is no doubt that the arrival and licensing of two tumour necrosis factor (TNF)-blocking drugs—infliximab and etanercept—for the treatment of ankylosing spondylitis (AS) represents the first major advance in the treatment of this condition since the advocacy of exercises and the introduction of phenylbutazone. These agents have also been shown unequivocally to be effective in a proportion of patients with psoriatic arthritis (PsA), comparable to their effect in rheumatoid arthritis (RA), and anecdotal reports also suggest benefits for patients with enteropathic arthritis, persistent reactive arthritis (ReA) and undifferentiated spondyloarthropathy (SpA). But, as with RA, the availability of these agents places a huge responsibility upon rheumatologists, individually and collectively, to negotiate the poorly charted waters of assessment of disease outcomes, known and potential drug toxicity and potentially massive cost. Moreover, all parties to the negotiation are signed up to the provision of such treatment according to criteria that are wise, transparent and fair. For the SpAs, the opportunities provided by TNFblockade come not a moment too soon but at a difficult time. In recent years huge expertise has developed in the assessment of RA and the development of suitable instruments for that purpose. In contrast, the SpAs have received much less clinical trial attention and clinicians are less well equipped to make objective assessments. Indeed, until the last few years few useful measures were available, especially for the assessment of spinal disease. Fortunately, several groups, notably that at Bath, UK, have developed and validated instruments for measuring such attributes as disease activity, function and pain in AS and more recently an international group of rheumatologists interested in AS have formed the Assessments in Ankylosing Spondylitis (ASAS) working group to attempt to reach consensus over treatment issues which cannot presently be governed by objective criteria such as the presence or absence of joint erosions. Thus, just in the nick of time, a basis has been laid on which to build a framework within which TNFblockade and other biological therapies can reasonably be used in the treatment of SpAs. Unfortunately, at present much of that framework relies heavily on subjective measures, with very limited objectivity. But the need for guidance is now, as our patients need treatment now. Such guidance as emerges must therefore be seen as provisional and requiring regular revision year on year.
Objectives. The aim of this study was to evaluate the effects of moderately intensive pool exercise therapy on patients with rheumatoid arthritis (RA).Methods. Forty-six patients with chronic RA were randomly assigned to a treatment group and a control group. The treatment group (n = 20) exercised in a temperate pool twice a week for 12 weeks. The control group (n = 23) continued with their previous activities. Aerobic capacity, measured by means of a submaximum bicycle test, and the physical component of the SF-36 were chosen as the primary outcome measures. Two tests of muscle endurance were chosen as the secondary outcome measure. Additional functional tests and instruments were included.Results. No significant differences between the groups were found for the primary outcome measures. Significant improvements in the following aspects of muscular function (P < 0.05) were found in the treatment group when their performance was compared with that of the control group: isometric shoulder endurance, grip force, dynamic endurance of lower extremities (chair test) and muscle function of lower extremities. Significant improvements were also found for vitality (SF-36) compared with the control group. The improvements in the training group were maintained for 3 months.Conclusions. Pool exercise therapy of moderate intensity significantly improved muscle endurance in the upper and lower extremities in patients with RA, while no impact on aerobic capacity was found. However, the study population was small and there is a need for further studies with larger populations.
OBJECTIVES:Leucocyte infiltration is the hallmark of vasculitis, chemokines being mainly responsible for leucocyte migration into inflamed tissues. The objective was to evaluate the local expression of chemokines and chemokine receptors in biopsies of patients with giant cell arteritis (GCA) compared with arteries from patients with polymyalgia rheumatica (PMR). We studied the expression of CCR5, CXCR3 and that of the Duffy antigen/receptor of chemokine (DARC), a chemokine internalizing receptor (interceptor), in parallel to the expression of the CCR5 ligand RANTES/CCL5.METHODS:Paraffin-embedded tissue sections from six patients with GCA and five patients with PMR were available for immunohistological analysis of chemokine receptor expression. RANTES/CCL5 mRNA was detected in tissue sections by in situ hybridization.RESULTS:In patients with biopsy-proven giant cell arteritis, CCR5 and CXCR3 were highly expressed by infiltrating leucocytes in involved tissue sections. Predominant clustering of CCR5+ and CXCR3+ leucocytes was found in the adventitia and was co-localized with the expression of CCL5/RANTES mRNA. Interestingly, we found marked expression of DARC on adventitial high endothelial venules in vasculitis lesions of patients with GCA, while in arteries from patients with PMR DARC was only expressed on a low number of vessels with flat lining endothelium.CONCLUSIONS:The co-localization of infiltrating CCR5+ and CXCR3+ leucocytes together with CCL5/RANTES and DARC in vasculitis lesions suggests a role for these chemokine receptors in leucocyte infiltration, possibly supported by DARC-mediated vascular presentation of chemokines.